Skip to content
PPepIndex

Evidence digest

What the research on ipamorelin actually shows

Ipamorelin has a small early-phase human literature that was not carried forward to approval. Development programmes are abandoned for many reasons — commercial, strategic and scientific — and the published record does not establish a durable clinical effect. A discontinued programme is not evidence of efficacy, and it is not evidence of harm either; it is an absence of conclusion.

Updated 22 Jul 2026 · 3 studies indexed · 3 human · compound record

Studies indexed
3
Human evidence
3
Preclinical only
0

What is and is not established

What the literature supports

  • A small early-phase human literature exists.
  • Preclinical work characterises it as a growth hormone secretagogue in animal models.

What is NOT established

  • No durable clinical effect is established in the indexed literature; at least one listed study reported no significant effect.
  • The development programme was not carried through to approval, and no regulator has approved it.
  • No long-term human safety data exists.
  • Why the programme stopped is not established by the published record and should not be inferred from it.

Studies indexed

3 human — controlled trial
Each row links to that study's permalink, where every digest citing it is listed. Findings are reported as the paper reported them — an animal result is not restated as a human one.
StudyEvidence typeModelnWhat it reportedSource
Early-phase human work on ipamorelinPubMed listingNull resultHuman — controlled trialNot recorded—Placeholder seed record. A small early-phase human literature exists. The development programme was not carried forward to approval, and the listed work does not establish a durable clinical effect.Listing
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patientsInternational journal of colorectal disease · 2014Human — controlled trialNot recorded—Postoperative ileus is a significant clinical challenge lacking effective management strategies. Ghrelin-receptor stimulation has promotility effects in the upper and lower gastrointestinal tract. This proof-of-concept, phase 2, randomized study evaluated the safety and efficacy of the ghrelin-receptor agonist ipamorelin in the treatment of postoperative ileus following abdominal surgery (ClinicalTrials.gov NCT00672074). The design was a multicenter, double-blind, placebo-con…PMID 25331030
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteersPharmaceutical research · 1999Human — controlled trialNot recorded—To examine the pharmacokinetics (PK) and pharmacodynamics (PD) of ipamorelin, a growth hormone (GH) releasing peptide, in healthy volunteers. A trial was conducted with a dose escalation design comprising 5 different infusion rates (4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutes) with eight healthy male subjects at each dose level. Concentrations of ipamorelin and growth hormone were measured. The PK parameters showed dose-proportionality, with a short terminal …PMID 10496658

Regulatory status

Full feed →
FDACompounding list

FDA bulk drug substances nominated for compounding — 503A and 503B lists

Placeholder seed entry recording the source, not an event. The FDA maintains categorised lists of bulk drug substances nominated for use in compounding, including substances it has evaluated and placed in the category that may not be compounded. Several peptides tracked in this index have appeared in these evaluations. PepIndex records movements between categories here as they are observed; the linked page is the authoritative listing.

SemaglutideBPC-157IpamorelinCJC-1295

WADAProhibited list

WADA Prohibited List — growth factors and peptide hormones (class S2)

Placeholder seed entry recording the source, not an event. The World Anti-Doping Agency publishes an annual Prohibited List; class S2 covers peptide hormones, growth factors, related substances and mimetics. Several compounds tracked in this index fall within that class or its catch-all clause. The list is revised annually and takes effect on 1 January. PepIndex records revisions affecting indexed compounds here.

IpamorelinCJC-1295TB-500

Vendors listing Ipamorelin

Ranked view →

The evidence above describes the published literature. What any individual vial contains is a separate question, answered by that vendor’s certificate records rather than by any study on this page.

VendorScore · CoverageCertificates
Curo93.877%2profile →
Polaris Peptides93.877%1profile →
Next Gen Peptides93.897%2profile →
Amino Club90.495%0profile →
Ascend Science90.291%1profile →
PeptidePlugs89.790%2profile →
Hydro Research Peptides88.289%1profile →
Prime Peptides87.180%1profile →
Protide Health83.994%0profile →
American Peptides83.6100%1profile →
Northline Labs79.493%1profile →
NeuroLabs Research79.386%1profile →
Koi Peptides79.394%0profile →
ZC Labs79.384%3profile →
Good Science Bio79.275%0profile →
Ascension Peptides78.186%3profile →
Licensed Peptides7789%1profile →
Modern Aminos74100%2profile →
Simple Peptide7489%2profile →
GenX Peptides70.868%0profile →
Eternal Peptides68.265%0profile →
BioLongevity Labs67.274%0profile →
Evolve Peptides65.567%0profile →
Mile High Compounds65.494%0profile →
Extreme Peptides64.282%1profile →
Sports Technology Labs56.174%0profile →

How to read this page

This digest describes what published research exists and what it does not establish. It is not a recommendation, contains no dosing information or protocols, and makes no claim that any compound is safe or effective for any purpose. Material listed by indexed vendors is labeled for laboratory research use only.